BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23624753)

  • 1. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
    Lu CC; Xu YQ; Wu JC; Hang PZ; Wang Y; Wang C; Wu JW; Qi JC; Zhang Y; Du ZM
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):747-55. PubMed ID: 23624753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
    Dai H; Jia G; Liu X; Liu Z; Wang H
    Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.
    Pan ZW; Zhang Y; Mei DH; Zhang R; Wang JH; Zhang XY; Xu CQ; Lu YJ; Yang BF
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Feb; 381(2):137-45. PubMed ID: 20052460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
    Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
    Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.
    Tsai CY; Kuo WW; Shibu MA; Lin YM; Liu CN; Chen YH; Day CH; Shen CY; Viswanadha VP; Huang CY
    PLoS One; 2017; 12(9):e0184153. PubMed ID: 28863192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway.
    Fang X; Liu Y; Lu J; Hong H; Yuan J; Zhang Y; Wang P; Liu P; Ye J
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1373-1385. PubMed ID: 30132020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.
    Tan X; Li J; Wang X; Chen N; Cai B; Wang G; Shan H; Dong D; Liu Y; Li X; Yang F; Li X; Zhang P; Li X; Yang B; Lu Y
    Int J Biol Sci; 2011 Apr; 7(3):383-9. PubMed ID: 21494433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca
    Xiao YF; Zeng ZX; Guan XH; Wang LF; Wang CJ; Shi H; Shou W; Deng KY; Xin HB
    J Cell Mol Med; 2018 Jul; 22(7):3638-3651. PubMed ID: 29682889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
    Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
    Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
    Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
    Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined inhibition of the CaMKIIδ and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy.
    Chen CH; Lin JW; Huang CY; Yeh YL; Shen CY; Badrealam KF; Ho TJ; Padma VV; Kuo WW; Huang CY
    J Cell Physiol; 2020 Apr; 235(4):3539-3547. PubMed ID: 31584202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choline protects against cardiac hypertrophy induced by increased after-load.
    Zhao Y; Wang C; Wu J; Wang Y; Zhu W; Zhang Y; Du Z
    Int J Biol Sci; 2013; 9(3):295-302. PubMed ID: 23493786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway.
    Lu M; Wang H; Wang J; Zhang J; Yang J; Liang L; Maslov LN
    Planta Med; 2014 Jan; 80(1):63-9. PubMed ID: 24338553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Ca2+/calmodulin-dependent protein kinase II and calcineurin in TNF-α-induced myocardial hypertrophy.
    Wang GJ; Wang HX; Yao YS; Guo LY; Liu P
    Braz J Med Biol Res; 2012 Nov; 45(11):1045-51. PubMed ID: 22832601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes.
    MacDonnell SM; Weisser-Thomas J; Kubo H; Hanscome M; Liu Q; Jaleel N; Berretta R; Chen X; Brown JH; Sabri AK; Molkentin JD; Houser SR
    Circ Res; 2009 Aug; 105(4):316-25. PubMed ID: 19608982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canstatin suppresses isoproterenol-induced cardiac hypertrophy through inhibition of calcineurin/nuclear factor of activated T-cells pathway in rats.
    Sugiyama A; Okada M; Yamawaki H
    Eur J Pharmacol; 2020 Mar; 871():172849. PubMed ID: 31843516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of transient receptor potential vanilloid 3 channel (TRPV3) aggravated pathological cardiac hypertrophy via calcineurin/NFATc3 pathway in rats.
    Zhang Q; Qi H; Cao Y; Shi P; Song C; Ba L; Chen Y; Gao J; Li S; Li B; Sun H
    J Cell Mol Med; 2018 Dec; 22(12):6055-6067. PubMed ID: 30299584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
    Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q
    Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasostatin-1 Stops Structural Remodeling and Improves Calcium Handling via the eNOS-NO-PKG Pathway in Rat Hearts Subjected to Chronic β-Adrenergic Receptor Activation.
    Wang D; Shan Y; Huang Y; Tang Y; Chen Y; Li R; Yang J; Huang C
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):455-464. PubMed ID: 27595734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.